AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
mTOR Inhibitors
mTOR inhibitors may play an important role in the management of advanced renal cell carcinoma
mTOR inhibition has been proven to result in:
- Reduced tumor cell growth and proliferation
- Decreased tumor angiogenesis
- Inhibited cell metabolism
One potential benefit of mTOR inhibitors is that they work downstream from other agents available to treat renal cell carcinoma, at the point where a number of important signaling pathways that are activated in renal cell carcinoma converge (see figure).
See how AFINITOR works. View the key data about AFINITOR, including results for progression-free survival and demonstrated efficacy.
Next: Cell Proliferation
